This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/mixture/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/kegg-compound/
n25http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n7http://www.drugs.com/mtm/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/pubchem-substance/
n9http://www.rxlist.com/cgi/generic/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01230/identifier/chemspider/

Statements

Subject Item
n2:DB01230
rdf:type
n3:Drug
n3:description
In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
n3:group
withdrawn illicit
n3:halfLife
The serum half-life of pemoline is approximately 12 hours.
n3:indication
For treatment of Attention Deficit Hyperactivity Disorder (ADHD)
owl:sameAs
n25:DB01230 n26:DB01230
dcterms:title
Pemoline
adms:identifier
n12:Pemoline n15:46509085 n16:PA450836 n17:4723 n18:D00744 n19:0074-6088-13 n20:C07899 n21:4561 n22:DB01230
n3:packager
n8:271B5ABE-363D-11E5-9242-09173F13E4C5 n8:271B5ABF-363D-11E5-9242-09173F13E4C5 n8:271B5ABD-363D-11E5-9242-09173F13E4C5 n8:271B5AC0-363D-11E5-9242-09173F13E4C5 n8:271B5AB9-363D-11E5-9242-09173F13E4C5 n8:271B5ABA-363D-11E5-9242-09173F13E4C5 n8:271B5ABB-363D-11E5-9242-09173F13E4C5 n8:271B5ABC-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Pemoline is excreted primarily by the kidneys with approximately 50% excreted unchanged and only minor fractions present as metabolites.
n3:toxicity
Side effects include insomnia, anorexia, stomach ache, skin rashes, increased irritability, mild depression, nausea, dizziness, headache, drowsiness, and hallucinations
n3:foodInteraction
Take without regard to meals. Avoid alcohol. Avoid high doses of caffeine.
n3:mixture
n5:271B5AB8-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Approximately 50% (bound to plasma proteins).
n13:hasConcept
n14:M0016107
foaf:page
n7:pemoline.html n9:pemoline.htm n23:cyl1109.shtml
n3:IUPAC-Name
n4:271B5AC5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5ACB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5ACA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5AC7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5AC8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5AC9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5AC3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5AC1-363D-11E5-9242-09173F13E4C5 n4:271B5AC4-363D-11E5-9242-09173F13E4C5 n4:271B5ADC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5AC2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5AD1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5AD2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5ACC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5ACD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5ACF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5ACE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5AD0-363D-11E5-9242-09173F13E4C5
n3:absorption
Pemoline is rapidly absorbed from the gastrointestinal tract
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
2152-34-3
n3:Bioavailability
n4:271B5AD7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5AD9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5ADA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5ADB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5AD6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5AD5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5AD8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5AC6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5AD3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5AD4-363D-11E5-9242-09173F13E4C5